Liquidia Technologies, which is developing engineered formulations of therapies for PAH and pain, raised $50 million by offering 4.55 million shares at $11, within the range of $10 to $12. Insiders had intended to purchase $30 million of the IPO (60% of the deal). At IPO, the company commands a fully diluted market value of $175 million.
Liquidia Technologies plans to list on the Nasdaq under the symbol LQDA. Jefferies and Cowen acted as lead managers on the deal.
